The medical industry is growing rapidly with the rising concern of diseases and makes this a richest market in the healthcare industry. However, with the more development in the technology of medicine making the medical industry is showing effective growth. According to the report analysis, ‘Duchenne Muscular Dystrophy – Pipeline Review, H2 2018’ states that Duchenne muscular dystrophy is a serious type of muscular dystrophy which causes muscles to gradually weaken over time. Learning difficulties, fatigue, muscle weakness, intellectual disability, progressive difficulty walking and several others are the major signs and symptoms of this disease. Moreover, the caused muscles may look larger because of increased fat content. Moreover, this disease affects nearly about 5,000 males at the time of birth and the average life expectancy is 26 and with the proper care many can live into their 30s or 40s. In addition, Gene Therapy is just like a treatment which is done early stages of study in humans.
Duchenne muscular dystrophy is caused by the change or problem in one of your gene as the genes carry important information of body which is important to make proteins and carry out many different functions of body. It appears that regions around the globe that do not have a strong risk factors which includes gender and family history. In this respect Asia Pacific region has gather the significant attention. The global instances described in the numerous health care organizations in the recent years. Moreover, major portion of the Asian countries reported cases of this disease along with European countries and the Americas. Furthermore, significant number of cases is registered by the North America region. Many other regions such as Africa have begun revolutionizing health care centers form procuring this disease in the country and the authorities of above countries have also started scattering warning and awareness to the general public related to the harmful effects and causes of this disease.
According to the report it is observed that the major topics which are covered for this disease includes Duchenne Muscular Dystrophy Therapeutic Products under Development, Key Players in Duchenne Muscular Dystrophy Therapeutics, Duchenne Muscular Dystrophy Pipeline Overview, Duchenne Muscular Dystrophy Pipeline, Duchenne Muscular Dystrophy Pipeline Assessment. On the other hand, report also covers major companies which are operating in this market produce the medicines such as Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Avidity Biosciences LLC, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, Biophytis SA, Capricor Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Cumberland Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Editas Medicine Inc, Eloxx Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, FibroGen Inc, Fulcrum Therapeutics Inc, Galapagos NV, Genethon SA, GTx Inc, GW Pharmaceuticals Plc, Italfarmaco SpA, Milo Biotechnology LLC, Mitobridge Inc, Mitochon Pharmaceuticals Inc, N-Gene Research Laboratories Inc, NicOx SA, Nobelpharma Co Ltd, Novartis AG, NS Pharma Inc, PeptiDream Inc, Pfizer Inc, Progenitor Therapeutics Ltd, PTC Therapeutics Inc, ReveraGen BioPharma Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Solid Biosciences Inc, SOM Biotech SL, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd, Teijin Pharma Ltd, WAVE Life Sciences Ltd and others.
In a research it is observed that many of the key players is functioning well for enabling the better treatment of this disease with the effective decision marking and built clinical trials, conferences which is helpful for the victims of this disease and for creating effective counter policies to gain competitive benefits. Therefore, in the coming years it is expected that global market of Duchenne muscular dystrophy healthcare pipeline will grow more significantly over the forecasted period with the introduction of more related projects on this disease.
For more information, click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/duchenne-muscular-dystrophy/154206-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
